Fig. 5: SARS-CoV-2 antibodies in patients, donors, and healthy controls. | Nature Communications

Fig. 5: SARS-CoV-2 antibodies in patients, donors, and healthy controls.

From: Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Fig. 5

A SARS-CoV-2 total Ig against SARS-CoV-2 receptor-binding domain (RBD) measured by Wantai ELISA. B SARS-CoV-2 IgM against SARS-CoV-2 RBD measured by Wantai ELISA. C Nucleocapsid IgG antibodies. D Nucleocapsid IgM antibodies. An independent Mann–Whitney U-test was used to evaluate SARS-CoV-2 total Ig and IgM against SARS-CoV-2 RBD measured by Wantai ELISA in the serum of COVID-19 patients (standard of care: red; convalescent plasma: blue) at enrollment (day 1). Nucleocapsid IgM and IgG antibodies were measured in the serum of COVID-19 patients (gray) at enrollment (day 1) in serum of donors (green) at week 6 post infection and in serum of healthy uninfected controls (brown). Box plots indicate median (middle line), 25th, 75th percentile (box), and 5th and 95th percentile (whiskers), as well as outliers (single points). Dashed line indicates positive cutoff at 1.0 OD ratio for both total Ig and IgM Wantai ELISA, and 11 units for both IgM and IgG nucleocapsid antibodies.

Back to article page